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Summary Although intra-luminal epidermal growth factor (EGF) may stimulate cell proliferation in the
upper gastrointestinal tract, its role in the large bowel has not been established. We have therefore studied the effect of intra-rectal EGF administration on both normal growth and carcinogenesis in the rat colon. Colonic
cancer was induced in rats with azoxymethane (10 mg kg- ' week-' for 12 weeks s.c.) and controls dosed with saline. In each group, animals were randomised to receive EGF (12 nM, 0.8 nM or saline control) in 0.5 ml saline via a rectal tube daily for 24 weeks. At this time, crypt cell production rates (CCPRs) were determined
at two sites in the colon: one of maximal and another of minimal exposure to EGF (5 cm and 10 cm from the anal margin respectively). No effects of EGF were seen at 10 cm. The lower dose of EGF gave CCPRs that mirrored the control values. The higher dose of EGF in the animals not treated with azoxymethane stimulated mucosal growth. Azoxymethane increased in CCPR, but this was suppressed by the high dose of EGF. These results suggest that (1) luminal EGF and azoxymethane independently increase the colonic CCPR and their combined effect is not synergistic but antagonistic; (2) EGF may have a role in normal epithelial growth, but does not potentiate colonic carcinogenesis in this model.
Epidermal Growth Factor (EGF) is a well characterised
polypeptide that exhibits mitogenic effects on a wide range of
cell types after binding to specific transmembrane receptors
(Cohen, 1983). In the gastrointestinal tract EGF is secreted
into the lumen by salivary (Starkey & Orth, 1977) and Brun-
ner's glands (Elder et al., 1978) and has been detected in the
luminal contents and mucosa throughout the intestine
(Schaudies et al., 1989). Whilst the physiological role of EGF
in the adult gut remains unclear, the demonstration of EGF
receptors on intestinal epithelial cells (Forgue-Lafitte et al.,
1980) indicates that the peptide may be involved in intestinal
homeostasis. In vivo studies that have examined the effects of
EGF on the intestine can be categorised into those where the
growth factor was administered systemically or those involv-
ing direct infusion into the gut lumen. Studies involving
intravenous administration of large amounts of EGF on a
short term basis have resulted in a stimulation of mucosal
growth throughout the small and large intestine (Dembinski
et al., 1982; Goodlad et al., 1987; Scheving et al., 1980).
However, as only small quantities of EGF are normally
found in blood (Byyny et al., 1974; Abe et al., 1987) when
compared to levels found in the gut lumen (Schaudies et al.,
1989) and as it is cleared from the circulation extremely
quickly (Jorgensen et al., 1988), luminal administration may
be the more relevant approach for such studies. Work in this
field has concentrated on the upper gastrointestinal tract
using large quantities of EGF and has yielded conflicting
results: some workers reported an EGF induced stimulation
of mucosal growth (Dembinski et al., 1982; Ulshen et al.,
1986), whilst others observed no significant mitogenic re-
sponse (Goodlad et al., 1987). Studies involving intracolonic
or long term EGF administration have not been described.
As EGF can stimulate mucosal growth throughout the
intestine and chemical carcinogenesis is promoted by hyper-
plasia of the target organ (Farber, 1981), especially in the
colon (Williamson & Rainey, 1984), it has been suggested
that EGF may play a role in intestinal carcinogenesis.
Indeed, EGF may be particularly important in the develop-
ment of colonic neoplasia as EGF receptors are over exp-
ressed in many large bowel carcinomas (Bradley et al., 1986).
The work to be described here, therefore, investigates the
effect of daily intracolonic EGF administration on the rat
large bowel during experimental colorectal carcinogenesis
and in untreated animals. Colonic epithelial growth was
assessed after 24 weeks of treatment.
Materials and methods
Experimentaldesign
Colonic cancer was induced in rats by subcutaneous injection of azoxymethane (1Omg/kg/week for 12 weeks). A control
group was similarly dosed with isotonic saline. In each
group, animals were randomised to receive one of three EGF
doses: 0.8 nM, 12 nM or a saline control dissolved in 0.5 ml of
saline (equal to 5, 75 or 0 ngml-'). This was administered
via a 7.0 cm, 18 gauge stainless steel animal feeding tube
(Popper and Sons Inc, Newhyde Park, NY 11040, USA) fully inserted through the anus into the colon. The treatment was
on a 5 day per week basis for 24 weeks and commenced with
the first azoxymethane injection.
Animals
Forty-eight adult male Wistar rats weighing between 350 and
400 g, at the start of the experiment, were housed in groups
of four with a 12 hour day/night cycle. Standard pelleted diet
(Labsure CRM, Poole, Dorset, UK) and water were pro-
vided ad libitum.
EGF
EGF was purified from mouse submaxillary glands (Savage & Cohen, 1972) and quantified using an extinction coefficient
of 30.9 (E",, at 280 nm). '25I labelled preparations of this
material specifically bound to human syncytiotrophoblast
microvillous membranes; a rich source of the EGF receptor
(Richards et al., 1983). Superimposable competitive binding
curves were obtained using three different EGF samples as
the unlabelled ligand. These were: (1) the mouse EGF
extracted for this study, (2) mouse EGF (a generous gift from H. Gregory, ICI, Alderley Park, Macclesfield, UK) and
(3) recombinant urogastrone/human EGF (Amersham Inter-
national plc, Amersham, UK). In a mitogenesis assay the
EGF preparation used in this study stimulated cell division in
mouse 3T3 fibroblasts at a concentration of 1.7 nM.
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Crypt cellproduction rates (CCPRs)
The CCPRs were determined by stathmokinetic techniques as
described in detail elsewhere (Goodlad & Wright, 1982).
On the morning before being killed, animals were given
1 mgkg-' vincristine sulphate (Oncovin, Eli Lilly, Basing-
stoke, UK) by intraperitoneal injection and killed at intervals
ranging from 30 to 156 min. The colon was removed immedi-
ately, opened longitudinally to expose the mucosa, rinsed in
isotonic saline, fixed in Carnoy's fluid for 6 h and stored in
70% ethanol.
Small pieces of colonic mucosa (2-3mm square), from
sampling sites at 5 and 10 cm from the anus in each rat, were
stained using the Fuelgen reaction and single crypts were
removed by microdissection. For each sample the number of
arrested metaphases in 40 crypts was determined. The mean
number of metaphases per crypt was plotted against time
(the interval between vincristine injection and tissue fixation).
The slope of the line was fitted by the method of least
squares and gave the rate of entry of cells into mitosis or the
crypt cell production rate. Differences in slopes were assessed
by a two-tailed Student's t test.
Distribution studies with radiolabelled EGF
'25I-labelled mouse EGF was prepared by the chloramine T
method (Hunter & Greenwood, 1962) to a specific activity of
150yCi ig-i. 0.5 ml of 4 nM radiolabelled EGF in saline was
administered into the colon of adult male rats by the method
described above. At intervals to 3 h the animals were killed
and 1 ml of blood was removed by cardiac puncture. The
intestine, liver, kidneys, spleen, thyroid and bladder contents
were removed. A gamma hand monitor was used to ensure
that no high concentrations of radioactivity remained in the
carcass. The radioactivity of contaminated fur, bedding,
faeces and excised tissues and fluids was measured in a LKB
gamma counter.
The macromolecular nature of the 1251, in tissues and fluids
containing sufficiently high levels, was assessed by trichloro-
acetic acid precipitation. 2 cm lengths of colon, the thyroid
gland and individual faecal pellets were homogenised in 3 ml
of 0.05 M acetic acid, spun at 6,000g(av) for 30 s and the
supernatant collected. The pellet was washed in a further
3 ml of acetic acid and respun and the supernatants were
combined. 0.1 ml of supernatant, urine or blood plasma was
added to 1.3 ml of a cold aqueous solution of 10% trichloro-
acetic acid and 1% phosphotungstic acid in 1.8 ml Eppendorf
tubes. 0.1 ml of 1% bovine serum albumin (carrier protein)
was added to make the total volume to 1.5 ml. The mixture
was left on ice for 60 min, spun at 6,000g(av) for 60 s and
the radioactivity in the precipitate (bound to macromole-
cules) and supernatant (free 1251) was measured.
Results
Animals
Before the end of the 24 week treatment period two animals
died from extensive metastases; both had been treated with
azoxymethane and rectal saline. All the remaining animals
were used for the CCPR determinations except for one where
post mitotic figures were present after the injection of vincris-
tine. A total of eight tumours were produced that were solely
in the animals treated with azoxymethane, but this was not
sufficient for statistical analysis.
Crypt cellproduction rates
(1) Non carcinogen group The results for this group are
summarised in Figure 1 and are expressed in cells per crypt
per hour ± the standard error. At the 5 cm sampling site the
CCPR for the saline controls and those receiving the lower
dose of EGF were similar (5.54 ± 1.51 and 4.27 ± 0.55). The
standard error associated with the saline treated group is
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Figure 2 Crypt cell production rates: Azoxymethane treated
group.
high and is heavily influenced by one point that lies outside
the 99.9% confidence limit of the regression line of the
others. On omission of this point the CCPR falls to 4.09 +
0.94. There is a statistically significant elevation of the CCPR
to 8.08 ± 0.75 in the group treated with the higher concentra-
tion of EGF when compared to the low dosed group (P<
0.001). When the higher dosed group is compared to the
saline treated animals there is no significant difference unless
the outlier is omitted (P<0.01).
At the 10cm sampling site, the values of the CCPR did
not differ significantly between the three groups with cell
turnover of 4.27 ± 0.97, 5.36 ± 1.06 and 4.22 ± 1.27 for the
controls, low and high dose EGF groups respectively.
(2) Carcinogen group The results are summarised in Figure
2. At the 5 cm sampling site the CCPRs for the animals
receiving intra-rectal saline or the lower dose of EGF were
elevated to 10.19 ± 0.97 and 9.44 ± 1.57 respectively. How-
ever, the rectal administration of 12 nM EGF resulted in a
significant suppression of the CCPR to 4.22 ± 1.27 compared
to the carcinogen animals receiving rectal saline (P< 0.005)
or the lower dose of EGF (P<0.05).
The CCPRs were not significantly different in all three
groups at the 10 cm sampling site with values of 6.97 ± 1.20,
5.46 ± 1.13 and 4.48 ± 0.62 for the controls, low and high
dose EGF groups respectively.
Studies with '25"-labelled EGF
The distribution of radioactivity at time points after rectal
administration was extremely variable. However, it is pos-
sible to make an estimation of the movement of the peptide
over a period of time. The following points were noted:
(1) A variable amount of radioactivity was lost from the
colon immediately after rectal administration.
(2) Thirty min after rectal administration of '251-labelled
EGF, radioactivity was detected in the distal 8 cm of theEGF EFFECTS ON COLONIC MUCOSAL GROWTH 225
colon. At 60 min a similar pattern of distribution was
observed. At 180 min the radioactivity had shifted to the
most distal 4 cm of the colon and rectum.
(3) The '25I in the colonic lumen remained greater than
90% trichloroacetic acid precipitable.
(4) Radioactivity was detected in the stomach and the
small intestine but not in anaesthetised rats suggesting that
EGF may have been taken up by coprophagy.
(5) 125I was found in the liver and kidneys, but not in
sufficient quantities to perform a trichloroacetic acid precipi-
tation. 1251I in the blood and urine was not bound to any
macromolecules. The thyroid gland showed high levels of
macromolecular radioactivity, but this was probably due to
the incorporation of iodine into stored thyroglobulin.
Discussion
This is the first study to involve chronic EGF administration
and EGF dosing via the intracolonic route. From the results,
it is clear that mucosal growth in the colon is influenced by
this treatment.
The radiolabelled EGF tracing studies showed that this
method of administration, via a rectal tube, gave a variable
dose. It is not possible to determine the absolute dose of
EGF received by a particular region of mucosa, nevertheless,
it is clear that the 10 cm sampling site was rarely in contact
with the rectally administered solution and if any contact
occurred it was for a short period of time. In contrast, the
5 cm site was in contact with the labelled peptide after every
dosing, for periods of up to 3 h.
A recent report has been helpful in determining the quan-
tity of EGF normally present in the rat colon. In a luminal
flush from the colon of 3 to 4 month old Sprague-Dawley
rats, the EGF content was 100 to 170 picograms per gram
body weight (Schaudies et al., 1989). As our rats were
350-400 g, we can estimate the total quantity of EGF in the
colonic lumen to be approximately 35 to 68 nanograms. In
our study, rectal administration of 0.5 ml of 0.8 nM EGF
(2.5 ng) may not have altered the growth factor levels, but
the higher dose of 12 nM (35.5 ng) was likely to have caused
a significant increase in the EGF concentration in the lumen
of the lower colon. This may explain why the higher dose of
EGF affected mucosal growth whereas the lower dose
mirrored the values of the controls. However, caution must
be exercised here. Although the radiolabel remaining in the
colon during the tracing studies was >90% trichloroacetic
acid precipitable, we have not determined whether all of this
radioactivity represented biologically active growth factor
available to colonic EGF receptors. In addition, many fac-
tors may contribute to the cumulative growth factor concen-
tration experienced by a particular region of mucosa after
long term rectal dosing. These could include the possibilities
that EGF binds to faecal matter, may not penetrate colonic
mucus layers or feedback mechanisms may exist that regulate
endogeneous growth factor levels.
As no significant effects of EGF were observed at the
10 cm sampling site, it is suggested that the growth factor
may have been having a local effect on the mucosa in the
lower colon and rectum rather than gaining access to the
blood and having a systemic mode of action on the entire
gut. However, there is no evidence to suggesting that the two
sites studied should be equally responsive to EGF. A small
quantity of free 1251I was detected in the blood during the
tracing studies suggesting that the rectal dosing may have
resulted in some growth factor entering the circulation.
Previous observations on the effects of continual intravenous
infusion of EGF on gut growth, although performed under
different conditions to our experiments, failed to produce a
stimulatory effect in the colon with 3 1g per rat per day (Goodlad et al., 1987). This produced a stable increase in
plasma EGF concentration ofapproximately 115 pg ml l.In
all our animals studied, the quantity of radiolabel detected in
the blood was not sufficient to suggest that plasma EGF
concentrations had increased by a fraction of these amounts.
The maximum levels of radioactivity detected in the blood
corresponded to less than 5 pg ml-' of EGF and in addition
was less than 5% TCA precipitable. We therefore feel that
any small amounts of EGF gaining access to the blood
stream were probably insignificant.
From this evidence we would like to suggest that EGF did
not cross the gut/blood barrier in significant quantities and
probably exerted its effect locally via functional EGF recep-
tors on the colonocytes. We would also like to suggest that
these receptors are on the apical membranes, as tight junc-
tions between adjacent cells should prevent the diffusion of
luminal EGF to basolateral membrane receptors. No conclu-
sive studies have been reported that describe receptor charac-
teristics or position on colonic cells. In the small intestine
their location is a matter of controversy with some reports
describing EGF receptors predominantly localised to the
brushborder membranes (Thompson, 1988), while others de-
scribe the receptors only on the basolateral membranes
(Scheving et al., 1989).
In our study, the colonic CCPRs of the groups treated
with rectally administered saline were similar to previously
reported values in both the carcinogen treated and control
animals (Cooke et al., 1984). The stimulatory effect of the
carcinogen was not seen at the 10 cm position in this study;
indeed, azoxymethane is known to produce a range of re-
sponses throughout the colon (Cooke et al., 1984). The
higher dose of EGF caused a significant stimulation of
mucosal growth at the 5 cm sampling site in the control
animals when compared to the animals receiving the lower
dose. The significance is marginal when the comparison is
made against the saline treated group (Figure 1); however,
the large standard error of this determination is heavily
influenced by one of the eight readings that deviates very
strongly from the regression line. On omission of this point,
the saline treated and high dose EGF treated groups are
significantly different. We feel that this is a relatively com-
mon problem and has been noted previously (Goodlad et al.,
1987), and the removal of such outliers is justifiable on the
grounds that parasites or other localised bowel infections
could account for such deviations. It is therefore clear that
the higher dose of EGF produced a stimulation of mucosal
cell growth that may be due to the mitogenic effect of this
growth factor. The same treatment, in the rats dosed with
azoxymethane, resulted in a suppression of mucosal cell turn-
over from the normally elevated levels (Figure 2). This result
was original and most surprising as other conditions that
produce mucosal hypertrophy have a synergistic effect with
azoxymethane (Williamson & Rainey, 1984).
There are few other studies that examine therelationship
between luminal EGF and colonic carcinogenesis. However,
sialadenectomy of rodents, a technique known to reduce
circulating EGF levels, has been used in conjunction with a
colonic carcinogen that is similar to azoxymethane, namely
1,2 dimethlyhydrazine (Li et al., 1982). This treatment results
in the production of fewer tumours than in the sham oper-
ated controls, and it has been suggested that this is a direct
result of reduced EGF levels and therefore contradicts our
data. However, the interpretation of this observation is not
straightforward. A similar study (Gut et al., 1987) indicated
that sialadenectomy induced a compensatory 3-fold increase
in duodenal EGF content which might actually increase lum-
inal EGF concentration in the colon.
As yet, we do not have an explanation for the differing
growth responses due to EGF of the azoxymethane treated
colonic mucosa when compared to the normal colonic
mucosa and we can only speculate. Suppression of growth by
EGF, w-hich has been reported in squamous cell carcinomas
in vitro (Barnes, 1982; Kamata et al., 1986) and in vivo with
Ehrlich ascites cells (Lombardero et al., 1986), may be related
to high cell surface EGF receptor density. Thus, overexpres-
sion of EGF receptors in the azoxymethane treated mucosa
may be responsible for the suppression of mucosal growth by
EGF. Alternatively, it is now known that transforming
growth factor alpha (TGFa), a peptide that binds to the
EGF receptor and has similar, but not identical biological226 J.R. REEVES et al.
activity to EGF (Burgess, 1989), is present in the colonic
mucosa of man in concentrations that exceed those of EGF
(Cartlidge & Elder, 1989). In addition, elevated levels of
TGFa, EGF and other high molecular weight EGF like
peptides have been identified in the intestinal mucosa of rats
treated with the colonic carcinogen 1,2 dimethylhydrazine
(Phylchenkov et al., 1989). Thus, elevated levels of TGFa
and other EGF like peptides may be present in the azoxy-
methane treated colonic mucosa. Addition of the rectally
administered EGF may result in down regulation of mucosal
EGF receptors and subsequent reduction in mucosal growth
rates.
Further studies are currently underway to characterise
EGF receptors in the colonic mucosa and to assess the effect
of EGF on the numbers of tumours formed by azoxy-
methane.
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